United States Epithelioid Sarcoma Treatment Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global epithelioid sarcoma treatment market reached US$ 1.32 billion in 2023 and is expected to reach US$ 2.66 billion by 2031 growing with a CAGR of 9.1% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/epithelioid-sarcoma-treatment-market?sb

Key Development:

United States: Recent Epithelioid Sarcoma Treatment Developments

✅ In January 2026, the FDA granted accelerated approval of tazemetostat (Tazverik®) as the first treatment specifically for metastatic or locally advanced epithelioid sarcoma patients not eligible for complete resection, marking a major milestone in targeted therapy for this rare cancer subtype.

✅ In July 2025, Calidi Biotherapeutics received FDA Fast Track designation for CLD‐201 (SuperNova), a first‐in‐class stem‐cell loaded oncolytic viral therapy for soft tissue sarcomas, including potential utility in epithelioid sarcoma, accelerating development and regulatory engagement.

✅ In the last month, multidisciplinary sarcoma expert discussions highlighted the emerging role of immunotherapy combinations and precision medicine approaches for rare sarcomas like epithelioid sarcoma presented at global oncology forums, emphasizing the need for histology‐specific trials.

✅ In late 2025, major clinical trials at institutions such as UCSF are exploring combination immunotherapies (e.g., nivolumab + ipilimumab) and novel ICI strategies in INI1‐negative sarcomas, offering potential future options beyond standard care.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=epithelioid-sarcoma-treatment-market

Japan: Recent Epithelioid Sarcoma Treatment Developments

✅ In September 2025, the Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation in Japan for tazemetostat (Tazverik®) for unresectable INI1‐negative epithelioid sarcoma after chemotherapy, underscoring support for rare cancer treatment development and regulatory incentives.

✅ In late 2025, a National Cancer Center Hospital Phase II investigator‐initiated trial (TAZETTA) of tazemetostat for unresectable or metastatic epithelioid sarcoma continued enrollment in Japan, aiming to generate local efficacy data and support future approval expansion.

✅ In the last 3 months, Japanese oncology communities focusing on genomic and molecular oncology (presented at JSMO/ESMO joint sessions) have stressed the integration of targeted agents like EZH2 inhibitors into sarcoma management pathways to improve outcomes in rare subsets like epithelioid sarcoma.

✅ Across 2025 research updates, multidisciplinary care approaches - combining surgery, systemic therapies, targeted therapy and immunotherapy insights have gained traction in Japan, reflecting a broader strategy to optimize treatment pathways for rare sarcomas including epithelioid sarcoma.

Key Players:

=> Ipsen, Janssen Pharmaceuticals, Novartis AG, Pfizer Inc., Baxter International, Teva Pharmaceuticals, Eisai Co. Ltd., Signa Healthcare, and Taiho Pharmaceuticals among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/epithelioid-sarcoma-treatment-market?sb

Key Segments:

By Type

Distal Type - ~45% share

Primarily includes cancers occurring at distal locations; majorly treated in hospitals and oncology centers.

Proximal Type - ~55% share

Includes cancers in proximal regions; increasing prevalence in developed regions drives higher market share.

By Treatment

Surgery - ~30% share

Standard treatment for early-stage cancers; widely adopted across hospitals and oncology centers.

Radiation Therapy - ~15% share

Used as standalone or adjuvant therapy, especially in combination with surgery or chemotherapy.

Chemotherapy - ~20% share

Conventional treatment, often combined with targeted therapies for better efficacy.

Combination Therapy - ~10% share

Integrates surgery, radiation, and/or chemotherapy to improve patient outcomes.

Targeted Drug Therapy - ~15% share

Growing adoption due to precision medicine advancements and lower side effects.

Others - ~10% share

Includes immunotherapy, hormonal therapy, and experimental treatments in clinical trials.

By End-User

Hospitals - ~40% share

Major channel for treatment, especially for early diagnosis and surgical interventions.

Oncology Centers - ~35% share

Specialized centers for cancer treatment, research, and advanced therapies.

Ambulatory Surgical Centers - ~15% share

Focused on minor surgeries, outpatient treatments, and post-operative care.

Others - ~10% share

Includes clinics, homecare services, and telemedicine providers supporting cancer management.

By Region

North America - ~35% share

Advanced healthcare infrastructure, high adoption of targeted therapies, and strong R&D.

Europe - ~25% share

Established oncology centers and government-supported cancer treatment programs.

Asia Pacific - ~20% share

Rapidly growing market due to rising cancer incidence, awareness, and healthcare investment.

Latin America - ~10% share

Emerging market with improving healthcare access and cancer treatment facilities.

Middle East & Africa - ~10% share

Developing infrastructure, increasing government initiatives, and adoption of modern therapies.

FAQ

What is the current size of the Epithelioid sarcoma treatment Market?

A: In 2023, the Epithelioid sarcoma treatment Market was valued at US$ 1.32 billion, reflecting its strong industry presence.

Q2: How large is the Epithelioid sarcoma treatment Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Epithelioid sarcoma treatment Market will grow to around US$ 2.66 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Epithelioid sarcoma treatment Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 9.1% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.